Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Lynx1 Capital Management LP
Form 13F · Q2 2026

Lynx1 Capital Management LP

CIK 1910456Filed 2026-08-1313F-HR/A View the filing on EDGAR ↗
$866M
Reported book value
27
Positions
12
Quarters on record
Top 50
Positions

Lynx1 Capital Management LP — holdings

Top 27 positions of 27, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1GHRS Gh Research Plc13.3M+23.2%$357M41.2%
2CGEM Cullinan Therapeutics Inc9.0M+0.0%$163M18.9%
3STOK Stoke Therapeutics Inc4.0M−15.2%$132M15.3%
4AGIO Agios Pharmaceuticals Inc3.4M+30.5%$127M14.6%
5CCCC C4 Therapeutics Inc7.3M+4.7%$34M4.0%
6KRRO Korro Bio Inc1.5M+0.0%$20M2.3%
7TCRX Tscan Therapeutics Inc8.0M+0.0%$8M0.9%
8DTIL Precision Biosciences Inc950,466−3.5%$7M0.9%
9NEUP Neuphoria Therapeutics Inc875,328+0.0%$4M0.4%
10PASG Passage Bio Inc673,759+8.0%$3M0.4%
11CGON Cg Oncology Inc31,391−0.6%$2M0.3%
12PLRX Pliant Therapeutics Inc1.8M—$2M0.2%
13TRDA Entrada Therapeutics Inc178,606−15.6%$1M0.2%
14VYNE THERAPEUTICS INC Vyne Therapeutics Inc1.6M+0.0%$1M0.1%
15PROQR THRAPEUTICS N V Proqr Thrapeutics N V521,413+661.3%$969,8280.1%
16TRAW Traws Pharma Inc559,470+3610.5%$471,8010.1%
17FHTX Foghorn Therapeutics Inc61,588—$300,5490.0%
18DNLI Denali Therapeutics Inc11,658−99.4%$299,8440.0%
19XNCR Xencor Inc18,194−96.6%$292,9230.0%
20ABSI Absci Corporation21,245+0.0%$246,2300.0%
21HOWL Werewolf Therapeutics Inc657,786+0.0%$236,7370.0%
22IMTX Immatics N.V23,236−89.3%$235,3810.0%
23AVTX Avalo Therapeutics Inc10,100—$186,6480.0%
24BOLT Bolt Biotherapeutics Inc30,800+0.0%$118,5800.0%
25NUVB Nuvation Bio Inc16,029—$91,0450.0%
26EPRX Eupraxia Pharmaceuticals Inc10,000—$66,1000.0%
27IKT Inhibikase Therapeutics Inc20,000—$40,6000.0%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.